How can we achieve universal access to low-cost treatment for HIV?

by Andrew M. Hill, Anton L. Pozniak
Published 2016-10-01

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

by Andrew Hill, Sophie L. Hughes, Dzintars Gotham, Anton L. Pozniak
Published 2018-04-01

Second European Round Table on the Future Management of HIV

by Casper Rokx, Douglas D. Richman, Michaela Müller-Trutwin, Guido Silvestri, Jan Lunzen, van, Saye Khoo, Mathias Lichterfeld, Marcus Altfeld, Carlo Federico Perno, Peter W. Hunt, Paddy Mallon, Jürgen K. Rockstroh, Anton L. Pozniak, Bonaventura Clotet, Charles A.B. Boucher
Published 2015-07-01

Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.

by Ai Kawana-Tachikawa, Josep M Llibre, Isabel Bravo, Roser Escrig, Beatriz Mothe, Jordi Puig, Maria C Puertas, Javier Martinez-Picado, Julia Blanco, Christian Manzardo, Jose M Miro, Aikichi Iwamoto, Anton L Pozniak, Jose M Gatell, Bonaventura Clotet, Christian Brander, MARAVIBOOST Investigators
Published 2014-01-01